+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Dalfampridine extended release: in multiple sclerosis



Dalfampridine extended release: in multiple sclerosis



Cns Drugs 24(10): 883-891



Dalfampridine extended release (ER) is an orally administered formulation of dalfampridine (fampridine, 4-aminopyridine), a potassium channel antagonist indicated for the improvement in walking ability in patients with multiple sclerosis (MS). Oral dalfampridine ER improved walking ability in patients with MS in three randomized, double-blind trials of up to 15 weeks' duration. In a phase II trial, percentage improvements in walking speed on the Timed 25-Foot Walk (T25FW) test (primary endpoint) were not significant versus baseline or placebo during treatment with dalfampridine ER 10, 15 or 20 mg twice daily. However, according to a post hoc analysis, response rates were significantly higher with dalfampridine ER than placebo, with a consistent mean improvement in walking speed of 25-29% seen in the pooled results from dalfampridine ER responders during the double-blind treatment period. In two phase III trials, the proportion of timed walk responders (primary endpoint) was significantly greater with dalfampridine ER 10 mg twice daily than with placebo, with improvements in walking speed of approximately 25% seen during dalfampridine ER treatment amongst timed walk responders. Interim results of noncomparative extensions of the two phase III trials showed that consistent improvements in walking speed were sustained above baseline for up to 2.5 years of dalfampridine ER treatment. Oral dalfampridine ER 10 mg twice daily was generally well tolerated in patients with MS, according to the results of the three randomized, double-blind, placebo-controlled trials.

(PDF emailed within 0-6 h: $19.90)

Accession: 052445720

Download citation: RISBibTeXText

PMID: 20839898

DOI: 10.2165/11205910-000000000-00000


Related references

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of Neurology 68(4): 494-502, 2010

Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial. International Journal of Ms Care 17(3): 138-145, 2015

Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment. Therapeutic Advances in Neurological Disorders 5(4): 199-204, 2012

The safety profile of dalfampridine extended release in multiple sclerosis clinical trials. Clinical Therapeutics 34(5): 1056-1069, 2012

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. Neuropsychiatric Disease and Treatment 7: 229-239, 2011

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis. Current Medical Research and Opinion 29(12): 1627-1636, 2014

Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis. Journal of Managed Care and Specialty Pharmacy 23(7): 771-780, 2018

A Randomized Crossover Trial of Dalfampridine Extended Release for Effect on Ambulatory Activity in People with Multiple Sclerosis. International Journal of Ms Care 18(4): 170-176, 2016

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States. Drug, Healthcare and Patient Safety 7: 169-174, 2016

Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets. Degenerative Neurological and Neuromuscular Disease 2: 53-64, 2019

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis. Therapeutics and Clinical Risk Management 11: 1-7, 2015

PND50 Estimation of the Effect of Dalfampridine Extended Release on Health Utility in Patients With Multiple Sclerosis Using Two Equations for Mapping the MSWS-12 to the EQ-5D. Value in Health 15(7): A554-A555, 2012

Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis. Clinicoeconomics and Outcomes Research 8: 177-186, 2016

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial. Clinical Therapeutics 37(12): 2780-2787, 2016

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis. Core Evidence 5: 107-112, 2010